Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion

References

• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• Bosis S, Mayer A, Esposito S. Meningococcal disease in childhood: epidemiology, clinical features and prevention. J Prev Med Hyg. 2015;56(3):E121–4.
   PubMedGoogle Scholar
• MacNeil JR, Blain AE, Wang X, et al. Current epidemiology and trends in meningococcal disease-United States, 1996-2015. Clin Infect Dis. 2018;66(8):1276–1281.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl):S12–20.
   PubMed Web of Science ®Google Scholar
• Taha MK, Weil-Olivier C, Bouée S, et al. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021;17(6):1858–1866. DOI:10.1080/21645515.2020.1849518
   PubMed Web of Science ®Google Scholar
• Cohn A, MacNeil J. The changing epidemiology of meningococcal disease. Infect Dis Clin North Am. 2015;29(4):667–677.
   PubMed Web of Science ®Google Scholar
• Peterson ME, Li Y, Bita A, et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9(1):010409. DOI:10.7189/jogh.09.010409
   PubMed Web of Science ®Google Scholar
• Nuttens C, Findlow J, Balmer P, et al. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Euro Surveill. 2022;27(3).
   PubMedGoogle Scholar
• Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–498. DOI:10.1016/j.jinf.2020.05.079
   PubMed Web of Science ®Google Scholar
• Balmer P, Burman C, Serra L, et al. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118–1130.
   PubMed Web of Science ®Google Scholar
• Boccalini S, Panatto D, Mennini FS, et al. Health Technology Assessment (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy. J Prev Med Hyg. 2021;62(1 Suppl 1):E1–128.
   Google Scholar
• Ministero della saulte. cited 12 Apr, 2022 Available from: https://www.salute.gov.it/portale/vaccinazioni/dettaglioContenutiVaccinazioni.jsp?lingua=italiano&id=4828&area=vaccinazioni&menu=vuoto.
   Google Scholar
• Martinón-Torres F, Bertrand-Gerentes I, Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Rev Vaccines. 2021;20(9):1123–1146.
   PubMed Web of Science ®Google Scholar
• Knuf M, Rämet M, Breinholt Staerke N, et al. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naive toddlers: a randomised, controlled trial. Hum Vaccin Immunother. 2022;18(5):2052657. DOI:10.1080/21645515.2022.2052657
   PubMed Web of Science ®Google Scholar
• Kensinger R, Arunachalam AB. Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi(R). Glycoconj J. 2022;39(3):381–392.
   PubMed Web of Science ®Google Scholar
• Khatun F, Stephenson RJ, Toth I. An Overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity. Chemistry. 2017;23(18):4233–4254.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Forsten A, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a phase II randomized study. Hum Vaccin Immunother. 2020;16(6):1306–1312. DOI:10.1080/21645515.2020.1733869
   PubMed Web of Science ®Google Scholar
• van der Vliet D, Vesikari T, Sandner B, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naive and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50. DOI:10.1017/S0950268821000261
   PubMed Web of Science ®Google Scholar
• Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e90. DOI:10.1017/S0950268821000698
   PubMed Web of Science ®Google Scholar
• Kirstein J, Pina M, Pan J, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a phase II randomized study. Hum Vaccin Immunother. 2020;16(6):1299–1305. DOI:10.1080/21645515.2020.1733868
   PubMed Web of Science ®Google Scholar
• Esteves-Jaramillo A, Koehler T, Jeanfreau R, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: a phase III randomized study. Vaccine. 2020;38(28):4405–4411. DOI:10.1016/j.vaccine.2020.04.067
   PubMed Web of Science ®Google Scholar
• Áñez G, Hedrick J, Simon MW, et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Hum Vaccin Immunother. 2020;16(6):1292–1298. DOI:10.1080/21645515.2020.1733867
   PubMed Web of Science ®Google Scholar
• Baccarini CI, Simon MW, Brandon D, et al. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-naive children 2–9 years of age: a phase III, randomized study. Pediatr Infect Dis J. 2020;39(10):955–960. DOI:10.1097/INF.0000000000002832
   PubMed Web of Science ®Google Scholar
• Chang LJ, Hedrick J, Christensen S, et al. A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560–3569. DOI:10.1016/j.vaccine.2020.03.017
   PubMed Web of Science ®Google Scholar
• Dhingra MS, Peterson J, Hedrick J, et al. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38(33):5194–5201. DOI:10.1016/j.vaccine.2020.06.013
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report. MenQuadfi. 2020 [ updated 17 September 2020; cited 31 Mar 2023]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/menquadfi-epar-public-assessment-report_en.pdf.
   Google Scholar
• European Medicines Agency. MenQuadfi summary of product characteristics. 2023. [ updated 1 March 2023; cited 27 Mar 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/menquadfi-epar-product-information_en.pdf.
   Google Scholar
• Piazza FM, Virta M, Paassilta M, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a phase III, open-label, multi-center study. Hum Vaccin Immunother. 2022;18(1):1–10. DOI:10.1080/21645515.2021.1902701
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• Peterson J, Deseda C, Julien K, et al. 03. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster dose in adults and adolescents vaccinated against meningococcal disease 3 - 6 years earlier [abstract]. Open for Infect Dis. 2021;8(Suppl_1):S125. DOI:10.1093/ofid/ofab466.206
   Google Scholar
• Robertson CA, Jacqmein J, Selmani A, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged >/=59 years: a phase III randomized study. Hum Vaccin Immunother. 2023;19(1):2160600. DOI:10.1080/21645515.2022.2160600
   PubMed Web of Science ®Google Scholar
• Ackerson BK, Sy LS, Glenn SC, et al. Pediatric vaccination during the COVID-19 pandemic. Pediatrics. 2021;148(1).
   PubMed Web of Science ®Google Scholar
• Castrejon MM, Leal I, de Jesus Pereira Pinto T, et al. The impact of COVID-19 and catch-up strategies on routine childhood vaccine coverage trends in Latin America: a systematic literature review and database analysis. Hum Vaccin Immunother. 2022;18(6):2102353.
   PubMed Web of Science ®Google Scholar
• Guedes S, Bertrand-Gerentes I, Evans K, et al. Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature. BMC Public Health. 2022;22(1):380. DOI:10.1186/s12889-022-12795-9
   PubMed Web of Science ®Google Scholar
• Cuesta Esteve I, Fernandez Fernandez P, Lopez Palacios S, et al. Health care professionals’ preference for a fully liquid, ready-to-use hexavalent vaccine in Spain. Prev Med Rep. 2021;22:101376.
   PubMedGoogle Scholar
• Del Pino M, Castellano VE, Pacchiotti AC, et al. Vaccination status in patients at risk for invasive disease with encapsulated bacteria at a children’s hospital in the City of Buenos Aires. Arch Argent Pediatr. 2023;121(1):e202202648. DOI:10.5546/aap.2022-02648.eng
   PubMedGoogle Scholar
• Pezzotti P, Miglietta A, Neri A, et al. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy. Vaccine. 2018;36(29):4222–4227. DOI:10.1016/j.vaccine.2018.06.002
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease. Surveillance 2023 [ updated March 6, 2023; cited 29 Mar 2023]. Available from: https://www.cdc.gov/meningococcal/surveillance/index.html.
   Google Scholar
• Lahra MM, George CR, Hogan TR. Australian meningococcal surveillance programme annual report, 2021. Commun Dis Intell. 2022;46. DOI:10.33321/cdi.2022.46.52
   Web of Science ®Google Scholar
• Gabutti G, Stefanati A, Kuhdari P. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. J Prev Med Hyg. 2015;56(3):E116–20.
   PubMedGoogle Scholar
• De Wals P, Deceuninck G, Lefebvre B, et al. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J. 2011;30(7):566–569. DOI:10.1097/INF.0b013e31820e8638
   PubMed Web of Science ®Google Scholar
• Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50(12):1601–1610. DOI:10.1086/652765
   PubMed Web of Science ®Google Scholar